ICI

DRUG5 trials

Sponsors

Groupe Hospitalier Pitie-Salpetriere, Sun Yat-sen University, Guangzhou University of Traditional Chinese Medicine, UMC Utrecht

Conditions

CancerCardiac ComplicationCardiomyopathiesCardiovascular DiseasesHeart DiseasesHepatocellular CarcinomaMetastatic CancerMyocarditis

Phase 1

Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound Histotripsy

RecruitingNCT06524570

UMC UtrechtCancer, Metastatic Cancer

Start: 2024-07-26End: 2030-08-01Target: 24Updated: 2026-02-18

Unknown Phase

Evaluation of Reporting of Immune Checkpoint Inhibitor Associated Cardio-vascular Adverse Reactions

CompletedNCT03387540

Groupe Hospitalier Pitie-SalpetriereCardiac Complication, Myocarditis

Start: 2017-12-02End: 2017-12-31Updated: 2019-09-26

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

RecruitingNCT04294771

Groupe Hospitalier Pitie-SalpetriereCardiomyopathies, Cardiovascular Diseases, Heart Diseases +3

Start: 2019-01-01End: 2030-01-01Target: 500000Updated: 2026-09-11

Comparison of HBV Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing ICI and Concurrent Antiviral Prophylaxis: a Prospective Observational Study

Sun Yat-sen UniversityHepatocellular Carcinoma

Start: 2020-12-25End: 2023-12-31Target: 800Updated: 2023-08-02

Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

RecruitingNCT05378334

Guangzhou University of Traditional Chinese MedicineNon-small Cell Lung Cancer

Start: 2022-06-15End: 2028-01-01Target: 82Updated: 2026-03-10

Related Papers

Data from HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/-L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study

2026-02-17

HBV Reactivation in Patients with Hepatocellular Carcinoma Treated with PD-1/L1 Antibodies and Concurrent Antiviral Prophylaxis Agents: A Prospective Observational Study.

2025-12-08

Immune checkpoint inhibitor-associated myocarditis: a novel risk score

European Heart Journal2025-06-1816 citations

Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing immune checkpoint inhibitor and concurrent antiviral prophylaxis agents: A prospective observational study.

Journal of Clinical Oncology2025-05-281 citations

Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept

Journal for ImmunoTherapy of Cancer2022-04-0186 citations

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.

2018-11-12891 citations